Fukushima Journalof Medical Science

Fukushima Society of Medical Science

Contact usPrivacy Policy

Abstract/References

Current issue
Archive

Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis

Shinji Nomura, Takafumi Watanabe, Reiko Honma, Susumu Matsukura, Emi Ito, Jun-ichi Imai, Yuichiro Kiko, Osamu Suzuki, Yuko Hashimoto, Manabu Kojima, Shigenori Furukawa, Shu Soeda, Shinya Watanabe, Keiya Fujimori

Author information

  • Shinji Nomura

    Department of Obstetrics and Gynecology, Fukushima Medical University

  • Takafumi Watanabe

    Department of Obstetrics and Gynecology, Fukushima Medical University

  • Reiko Honma

    Nippon Gene Co., Ltd.

  • Susumu Matsukura

    Medicrome Inc.

  • Emi Ito

    Translational Research Center, Fukushima Medical University

  • Jun-ichi Imai

    Translational Research Center, Fukushima Medical University

  • Yuichiro Kiko

    Department of Diagnostic Pathology, Fukushima Medical University

  • Osamu Suzuki

    Department of Diagnostic Pathology, Fukushima Medical University

  • Yuko Hashimoto

    Department of Diagnostic Pathology, Fukushima Medical University

  • Manabu Kojima

    Department of Obstetrics and Gynecology, Fukushima Medical University

  • Shigenori Furukawa

    Department of Obstetrics and Gynecology, Fukushima Medical University

  • Shu Soeda

    Department of Obstetrics and Gynecology, Fukushima Medical University

  • Shinya Watanabe

    Translational Research Center, Fukushima Medical University

  • Keiya Fujimori

    Department of Obstetrics and Gynecology, Fukushima Medical University

Abstract

Aim:Ovarian serous carcinoma (OSC) and ovarian clear cell carcinoma (OCCC) are two major histological types of epithelial ovarian carcinoma (EOC), each with different biological features and clinical behaviors. Although immunostaining is commonly used for differential diagnosis between OSC and OCCC, correct identification of EOC with mixed-type histology is sometimes a diagnostic challenge. The aim of the present study was to explore candidate genes as potential diagnostic biomarkers that distinguish OSC from OCCC.


Methods:A total of 57 surgical specimens were obtained from EOC patients who had previously undergone primary debulking surgery. Total RNAs were extracted from fresh-frozen tissues of EOC patients, and were used for comprehensive gene expression analysis using DNA microarray technology.


Results:Ten candidate genes, FXYD2, TMEM101, GABARAPL1, ARG2, GLRX, RBPMS, GDF15, PPP1R3B, TOB1, and GSTM3 were up-regulated in OCCC compared to OSC. All EOC patients were divided into two groups according to hierarchical clustering using a 10-gene signature.


Conclusion:Our data suggest that the 10 candidate genes would be an excellent marker for distinguishing OSC from OCCC. Furthermore, the molecular signatures of the 10 genes may enlighten us on the differences in carcinogenesis, and provide a theoretical basis for OCCC’s resistance to chemotherapy in the future.


The cintent of reseach paper

References

1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world:epidemiology and risk factors. Int J Womens Health, 11:287-299, 2019.


2. Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer, 60:49-58, 2016.


3. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol, 109:370-376, 2008.


4. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II:reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer, 15:668-679, 2015.


5. Babaier A, Mal H, Alselwi W, Ghatage P. Low-Grade Serous Carcinoma of the Ovary:The Current Status. Diagnostics (Basel), 12:458, 2022.


6. Ku FC, Wu RC, Yang LY, Tang YH, Chang WY, Yang JE, et al. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas:Results from a single-center Taiwanese study. J Formos Med Assoc, 117:117-125, 2018.


7. Takano M, Tsuda H, Sugiyama T. Clear cell carcinoma of the ovary:is there a role of histology-specific treatment? J Exp Clin Cancer Res, 31:53, 2012.


8. Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy:An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol, 147:243-249, 2017.


9. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol, 33:14-21, 2009.


10. Zhou H, Liu Q, Shi X, Liu Y, Cao D, Yang J. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma. J Ovarian Res, 13:38, 2020.


11. Watanabe T, Honma R, Kojima M, Nomura S, Furukawa S, Soeda S, et al. Prediction of lymphovascular space invasion in endometrial cancer using the 55-gene signature selected by DNA microarray analysis. PLoS One, 14:e0223178, 2019.


12. Tada T, Honma R, Imai JI, Saze Z, Kogure M, Marubashi S, et al. A novel gene expression scoring system for accurate diagnosis of basaloid squamous cell carcinoma of the esophagus. Int J Oncol, 51:877-886, 2017.


13. Iida Y, Okamoto A, Hollis RL, Gourley C, Herrington CS. Clear cell carcinoma of the ovary:a clinical and molecular perspective. Int J Gynecol Cancer, 31:605-616, 2021.


14. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary:a review of the literature. Gynecol Oncol, 126:481-490, 2012.


15. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. Expression profiling in ovarian clear cell carcinoma:identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol, 163:2503-2512, 2003.


16. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell, 14:4376-4386, 2003.


17. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res, 62:4722-4729, 2002.


18. Hsu IL, Chou CY, Wu YY, Wu JE, Liang CH, Tsai YT, et al. Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma. Oncotarget, 7:62925-62938, 2016.


19. Rodriguez AR, de Sevilla Müller LP, Brecha NC. The RNA binding protein RBPMS is a selective marker of ganglion cells in the mammalian retina. J Comp Neurol, 522:1411-1443, 2014.


20. Hanschmann EM, Godoy JR, Berndt C, Hudemann C, Lillig CH. Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance:from cofactors to antioxidants to redox signaling. Antioxid Redox Signal, 19:1539-1605, 2013.


21. Yu DD, Guo SW, Jing YY, Dong YL, Wei LX. A review on hepatocyte nuclear factor-1beta and tumor. Cell Biosci, 5:58, 2015.


22. Bártů M, Dundr P, Němejcová K, Tichá I, Hojný H, Hájková N. The Role of HNF1B in Tumorigenesis of Solid Tumours:a Review of Current Knowledge. Folia Biol (Praha), 64:71-83, 2018.


23. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol, 38:1074-1080, 2007.


24. Lee HS, Kundu J, Kim RN, Shin YK. Transducer of ERBB2.1 (TOB1) as a Tumor Suppressor:A Mechanistic Perspective. Int J Mol Sci, 16:29815-29828, 2015.


25. Wang S, Yang J, You L, Dai M, Zhao Y. GSTM3 Function and Polymorphism in Cancer:Emerging but Promising. Cancer Manag Res, 12:10377-10388, 2020.


26. Watson MB, Lind MJ, Smith L, Drew PJ, Cawkwell L. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model. Acta Oncol, 46:651-658, 2007.


27. Jacquet M, Guittaut M, Fraichard A, Despouy G. The functions of Atg8-family proteins in autophagy and cancer:linked or unrelated? Autophagy, 17:599-611, 2021.


28. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J, 281:1750-1758, 2014.


29. Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q, et al. Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma, 62:432-438, 2015.


30. Zhou H, Shen Q, Fu J, Jiang F, Wang L, Wang Y. Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma. J Clin Lab Anal, 34:e23312, 2020.


31. Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular Characterization of Epithelial Ovarian Cancer:Implications for Diagnosis and Treatment. Int J Mol Sci, 17:2113, 2016.

Figures